Hatada I, Nabetani A, Morisaki H, Xin Z, Ohishi S, Tonoki H, Niikawa N, Inoue M, Komoto Y, Okada A, Steichen E, Ohashi H, Fukushima Y, Nakayama M, Mukai T
National Cardiovascular Center Research Institute, Osaka, Japan.
Hum Genet. 1997 Oct;100(5-6):681-3. doi: 10.1007/s004390050573.
Beckwith-Wiedemann syndrome (BWS) is characterized by numerous growth abnormalities and an increased risk of childhood tumors. The gene for BWS is localized in the 11p15.5 region, as determined by linkage analysis of autosomal dominant pedigrees. The increased maternal transmission pattern seen in the autosomal dominant-type pedigrees and the findings of paternal uniparental disomy reported for a subgroup of patients indicate that the gene for BWS is imprinted. Previously, we found p57KIP2, which is a Cdk-kinase inhibitor located at 11p15, is mutated in two BWS patients. Here, we screened for the mutation of the gene in 15 BWS patients.
贝克威思-维德曼综合征(BWS)的特征是存在多种生长异常以及儿童期肿瘤风险增加。通过常染色体显性谱系的连锁分析确定,BWS基因定位于11p15.5区域。在常染色体显性型谱系中观察到的母系传递增加模式以及部分患者报道的父源单亲二体现象表明,BWS基因是印记基因。此前,我们发现位于11p15的细胞周期蛋白依赖性激酶抑制剂p57KIP2在两名BWS患者中发生了突变。在此,我们对15名BWS患者进行了该基因的突变筛查。